Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI
European Radiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 27, 2025
Abstract
Objectives
This
study
aimed
to
assess
whether
pharmacokinetic
parameters
derived
from
DCE-MRI
can
stratify
Programmed
Death-Ligand
1
(PD-L1)
expression
in
NSCLC.
The
secondary
aim
was
identify
a
suitable
model
configuration
for
anisotropic
temporally-spaced
sequences,
considering
Tofts
variants,
population-averaged
arterial
input
functions
(AIF),
and
bolus
arrival
time
(BAT)
estimation
methods.
Materials
methods
From
April
2021
May
2023,
patients
with
locally
advanced
non-small
cell
lung
cancer
(NSCLC)
were
prospectively
enrolled.
Tumors
categorized
based
on:
PD-L1
absence/presence
(threshold
1%)
hyperexpression/hypoexpression
50%).
Pharmacokinetic
extracted
using
several
candidate
configurations;
fit
quality
evaluated
coefficient
of
determination
(
R
²).
Mann–Whitney
U-test
ROC-AUC
used
correlation
the
best-fit
configuration.
Results
Thirty-eight
(mean
age
68
±
9
years,
28
men)
included.
present
25
(66%)
absent
13
(34%).
hyperexpressed
(34%)
hypoexpressed
(66%).
Voxel-wise
configuration—extended
(ETM)
Georgiou
AIF
Peak-Gradient
(PG)
BAT
2
=
0.79).
K
trans
median
(0.25
vs.
0.12
min
−
¹,
p
0.02),
standard
deviation
(0.32
0.23
0.01)
ep
(1.09
0.59
0.02)
significantly
higher
<
50%
group
(ROC-AUC
0.71–0.76).
Conclusion
could
hypo/hyperexpression
ETM
PG
method
best-performing
Key
Points
Question
Could
Dynamic
Contrast-Enhanced
(DCE)
MRI
offer
safe
non-invasive
way
expression?
Findings
Quantitative
(the
volume
transfer
rate)
efflux
rate
constant)
show
potential
distinguishing
hyperexpression
hypoexpression.
Clinical
relevance
Preliminary
results
suggest
that
be
cancer,
potentially
optimizing
treatment
decisions,
given
high
cost
immunotherapy.
Graphical
Language: Английский
Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients
BioMedical Engineering OnLine,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: May 16, 2025
To
investigate
the
clinical
efficacy,
incidence
of
radiation
pneumonitis,
and
impact
on
lung
function
sequential
chemoradiotherapy
(SCRT)
concurrent
(CCRT)
in
treatment
cancer.
From
January
2020
to
December
2022,
158
patients
with
non-small
cell
cancer
(NSCLC)
were
admitted
our
hospital
chosen
as
study
subjects.
Their
data
analyzed
retrospectively
organized
into
a
control
group
(n
=
78,
received
SCRT)
an
observation
80,
CCRT).
Lesion
sizes
measured
through
CT
scans
used
compare
efficacy
between
two
groups.
The
also
compared
rates
adverse
reactions,
pre-
post-treatment,
including
forced
expiratory
volume
one
second
(FEV1),
vital
capacity
(FVC),
FEV1/FVC
ratio.
comparison
serum
tumor
marker
levels
was
conducted
groups,
being
observed
over
36-month
period.
Kaplan-Meier
survival
curves
analyze
changes
overall
rate
(OSR),
progression-free
(PFS),
(OS)
groups
patients.
For
group,
remission
90.00%,
for
it
74.36%.
96.25%
89.74%
group.
Significantly
higher
than
(P
<
0.05).
hemoglobin
reduction
grade
0
81.2%
58.9%
In
terms
leukopenia
(grades
0-III)
0-II),
outperformed
25.00%
experienced
8.97%
Overall,
more
severe
radiation-induced
injury
6.41%
cases
reaching
IV,
unlike
0.00%
Grade
II
accounted
1.28%
figure
significantly
lower
21.25%
Post-treatment,
FEV1,
FVC,
values
rose
both
displaying
greater
increases
Also,
after
treatment,
there
decrease
CA125,
SCC
Ag,
CYFRA21-1
having
According
curve
analysis,
achieved
OSR
which
exceeded
83.33%
>
Furthermore,
PFS
OS
elevated
relative
CCRT
could
optimize
effect
NSCLC
by
improving
function,
reducing
levels,
prolonging
without
increasing
toxicity.
Nonetheless,
occurrence
pneumonitis
somewhat
above
expectations,
plan
should
be
tailored
patient's
specific
circumstances
practice.
Language: Английский
Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers
Cancer Control,
Journal Year:
2024,
Volume and Issue:
31
Published: Jan. 1, 2024
Background
Immune
therapy,
especially
involving
PD-1/PD-L1
inhibitors,
has
shown
promise
as
a
therapeutic
option
for
cholangiocarcinoma.
However,
limited
studies
have
evaluated
survival
outcomes
in
cholangiocarcinoma
patients
treated
with
immune
therapy.
This
study
aims
to
develop
predictive
model
evaluate
the
benefits
of
therapy
Methods
retrospective
analysis
included
120
from
Shulan
(Hangzhou)
Hospital.
Univariate
and
multivariate
Cox
regression
analyses
were
conducted
identify
factors
associated
following
A
was
constructed
validated
using
calibration
curves
(CC),
decision
curve
(DCA),
concordance
index
(C-index),
receiver
operating
characteristic
(ROC)
curves.
Results
identified
several
potential
predictors
post-immune
cholangiocarcinoma:
treatment
cycle
(<6
vs
≥
6
months,
95%
CI:
0.119-0.586,
P
=
0.001),
neutrophil-to-lymphocyte
ratio
(NLR
<3.08
3.08,
1.864-9.624,
carcinoembryonic
antigen
(CEA
<4.13
4.13,
1.175-5.321,
0.017),
presence
bone
metastasis
(95%
1.306-6.848,
0.010).
The
nomogram
achieved
good
accuracy
C-index
0.811.
CC
indicated
strong
between
predicted
observed
outcomes.
Multi-timepoint
ROC
at
1,
2,
3
years
model’s
performance
(1-year
AUC:
0.906,
2-year
0.832,
3-year
0.822).
multi-timepoint
DCA
also
demonstrated
higher
net
benefit
compared
extreme
Conclusion
model,
incorporating
key
risk
demonstrates
robust
outcomes,
offering
improved
clinical
decision-making.
Language: Английский